tiprankstipranks
Trending News
More News >
Santhera Pharmaceuticals Holding Ag (CH:SANN)
:SANN
Advertisement

Santhera Pharmaceuticals Holding (SANN) Price & Analysis

Compare
2 Followers

SANN Stock Chart & Stats

CHF9.58
-CHF0.14(-0.88%)
At close: 4:00 PM EST
CHF9.58
-CHF0.14(-0.88%)

Bulls Say, Bears Say

Bulls Say
Distribution AgreementsAn exclusive distribution agreement for vamorolone has been established in Russia, allowing access to AGAMREE for Duchenne muscular dystrophy patients across the country.
Financial PerformanceSanthera expects FY2025 top-line revenue to exceed the previously stipulated guidance range, suggesting stronger financial performance.
Sales GrowthVamorolone direct sales growth is accelerating in Germany, with increasing use beyond the initial pediatric cohort and rising combination therapy with DUVYZAT™.
Bears Say
Market RisksRisks include, but are not limited to: setbacks with vamorolone in areas beyond DMD, partnership risks, slower-than-projected market uptake for vamorolone in the U.S. and EU, inability to optimize vamorolone's value in other countries and territories, currency risks due to a decline in the relative value of the U.S. dollar, and possible medium- to long-term dilution risk.

Santhera Pharmaceuticals Holding News

SANN FAQ

What was Santhera Pharmaceuticals Holding Ag’s price range in the past 12 months?
Santhera Pharmaceuticals Holding Ag lowest stock price was CHF7.21 and its highest was CHF17.76 in the past 12 months.
    What is Santhera Pharmaceuticals Holding Ag’s market cap?
    Santhera Pharmaceuticals Holding Ag’s market cap is CHF130.55M.
      When is Santhera Pharmaceuticals Holding Ag’s upcoming earnings report date?
      Santhera Pharmaceuticals Holding Ag’s upcoming earnings report date is Apr 23, 2026 which is in 188 days.
        How were Santhera Pharmaceuticals Holding Ag’s earnings last quarter?
        Santhera Pharmaceuticals Holding Ag released its earnings results on Sep 23, 2025. The company reported -CHF3.04 earnings per share for the quarter, missing the consensus estimate of -CHF0.6 by -CHF2.44.
          Is Santhera Pharmaceuticals Holding Ag overvalued?
          According to Wall Street analysts Santhera Pharmaceuticals Holding Ag’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Santhera Pharmaceuticals Holding Ag pay dividends?
            Santhera Pharmaceuticals Holding Ag does not currently pay dividends.
            What is Santhera Pharmaceuticals Holding Ag’s EPS estimate?
            Santhera Pharmaceuticals Holding Ag’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Santhera Pharmaceuticals Holding Ag have?
            Santhera Pharmaceuticals Holding Ag has 14,010,270 shares outstanding.
              What happened to Santhera Pharmaceuticals Holding Ag’s price movement after its last earnings report?
              Santhera Pharmaceuticals Holding Ag reported an EPS of -CHF3.04 in its last earnings report, missing expectations of -CHF0.6. Following the earnings report the stock price went down -14.141%.
                Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding Ag?
                Currently, no hedge funds are holding shares in CH:SANN

                Company Description

                Santhera Pharmaceuticals Holding Ag

                Santhera Pharmaceuticals Holding AG (SANN) is a Swiss biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare diseases, primarily neuromuscular disorders. The company is committed to addressing unmet medical needs by leveraging its expertise in drug development and its strategic partnerships. Santhera's core products include therapies for conditions such as Duchenne muscular dystrophy and other rare diseases, utilizing both proprietary and licensed technologies to enhance patient outcomes.

                Santhera Pharmaceuticals Holding (SANN) Earnings & Revenues

                SANN Company Deck

                SANN Earnings Call

                Q2 2025
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summaries

                SANN Stock 12 Month Forecast

                Average Price Target

                CHF29.74
                ▲(210.46% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"CHF7","30":"CHF30","12.75":"CHF12.75","18.5":"CHF18.5","24.25":"CHF24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29.7422025627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF29.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.7422025627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF29.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.7422025627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF29.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,12.75,18.5,24.25,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Feb<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.48,11.961707889438461,13.443415778876924,14.925123668315386,16.406831557753847,17.888539447192308,19.37024733663077,20.851955226069233,22.333663115507694,23.815371004946154,25.29707889438462,26.77878678382308,28.26049467326154,{"y":29.7422025627,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.48,11.961707889438461,13.443415778876924,14.925123668315386,16.406831557753847,17.888539447192308,19.37024733663077,20.851955226069233,22.333663115507694,23.815371004946154,25.29707889438462,26.77878678382308,28.26049467326154,{"y":29.7422025627,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.48,11.961707889438461,13.443415778876924,14.925123668315386,16.406831557753847,17.888539447192308,19.37024733663077,20.851955226069233,22.333663115507694,23.815371004946154,25.29707889438462,26.77878678382308,28.26049467326154,{"y":29.7422025627,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.59,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.81,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.84,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Molecular Partners AG
                Basilea Pharmaceutica
                Idorsia Ltd
                Newron Pharmaceuticals SpA
                Xlife Sciences Ltd.

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis